Journal article

The Rare Anaphylaxis-Associated FcγRIIa3 Exhibits Distinct Characteristics From the Canonical FcγRIIa1

JC Anania, HM Trist, CS Palmer, PS Tan, BP Kouskousis, AM Chenoweth, SJ Kent, GA Mackay, A Hoi, R Koelmeyer, C Slade, VL Bryant, PD Hodgkin, PM Aui, MC van Zelm, BD Wines, PM Hogarth

Frontiers in Immunology | FRONTIERS MEDIA SA | Published : 2018

Abstract

FcγRIIa is an activating FcγR, unique to humans and non-human primates. It induces antibody-dependent proinflammatory responses and exists predominantly as FcγRIIa1. A unique splice variant, we designated FcγRIIa3, has been reported to be associated with anaphylactic reactions to intravenous immunoglobulins (IVIg) therapy. We aim to define the functional consequences of this FcγRIIa variant associated with adverse responses to IVIg therapy and evaluate the frequency of associated SNPs. FcγRIIa forms from macaque and human PBMCs were investigated for IgG-subclass specificity, biochemistry, membrane localization, and functional activity. Disease-associated SNPs were analyzed by sequencing geno..

View full abstract

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

This work was funded by Australian National Health and Medical Research Council PMH, JA, AC, and BW supported by project grants 1079946, 1067484, and grants-in-aid from the Pendergast Trust, Rebecca Cooper Foundation and Walkom Trust. PDH and VB supported by NHMRC Program Grant 1054925, Project Grant 1127198. MCvZ was supported by NHMRC Senior Research Fellowship. CS supported by NHMRC postgraduate scholarship 1075666. VB also supported by Holmes Trust, Bloody Long Way, and WEHI Innovation Grant.